News7News 7
HomeNewsAvance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical

Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical

by News7
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical

WAKE FOREST, N.C. | ADELAIDE, AUS, MAY 31, 2024 – (ACN Newswire) – Avance Clinical, the award-winning Australian and North American CRO for biotechs, has signed a Memorandum of Understanding (MOU) with Julius Clinical, a leading CNS, cardiometabolic, and rare diseases specialist CRO with extensive site relationships across Europe. The non-exclusive MOU between the two offers a streamlined global solution for both their biotech clients.

Avance Clinical CEO Yvonne Lungershausen said “Julius Clinical are an ideal partner for Avance Clinical because they lead with scientific expertise and can support our biotech clients with specialist CNS, cardiometabolic and rare diseases clinical operations and site relationships in Europe. Julius Clinical clients can also leverage Avance Clinical operations in Asia, Australia, New Zealand and North America for their expanded later phase trials”.

Martijn Wallert, CEO of Julius Clinical, added, “We are excited to be partnering with Avance Clinical. Biotechs seek partners that can start quickly with high-quality data accepted by regulatory agencies like the MHRA, EMA, and US FDA. Together with Avance Clinical, we offer a nimble, flexible, and scientifically robust service, providing a tailored global solution”. Julius Clinical has supported over 380 clinical trials, enrolling some 220,000 participants in around 39 countries.

Avance Clinical is committed to accelerating drug development for biotech clients from early to later phase trials, with study data accepted by regulatory authorities including the EMA and FDA, allowing clients to remain with one CRO throughout their clinical development program. “This is our GlobalReady program, currently utilized by more than 90 biotech clients. Our globalized strategy ensures efficiency at every step,” Lungershausen said.

“In addition to our existing operations, our specialist partner CROs work alongside our teams to ensure our biotech clients benefit from the most experienced scientific, regulatory, and clinical operations teams across various therapeutic areas and regions.  Avance Clinical is now a global CRO for biotechs.”

Meet Avance Clinical at BIO 2024 – Book a meeting.

About Avance Clinical

Avance Clinical is the largest premium full-service Australian and North American CRO delivering quality clinical trials with globally accepted data, in Australia, New Zealand and the US. The company’s clients are completing Phase I to Phase III of drug development programs which require fast, agile, and adaptive solution-oriented clinical research services. Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than 26 years.

Avance Clinical offers pre-clinical services with their experienced ClinicReady team from pre-clinical through to Phase III clinical services, leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes. With experience across more than 120 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review. Avance Clinical uses state-of-the-art technology and systems across all functional areas. Tech partners include Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio. Learn more at www.avancecro.com.

About Julius Clinical

Julius Clinical, founded in 2008 and based in Zeist, The Netherlands, is a scientifically focused CRO providing end-to-end clinical trial service to pharmaceutical and biotechnology customers, as well as governments and academia. Julius Clinical’s renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a global network of research sites to deliver tailor-made solution for customers and their clinical trials. With a focus on the therapeutic areas of CNS, cardio-metabolic, renal, and rare diseases, Julius Clinical has grown to approximately 200 employees and has supported over 380 clinical trials, enrolling more than 220,000 participants in around 39 countries. Visit www.juliusclinical.com.


Kate Thompson,
Avance Clinical
[email protected]


Topic: Press release summary


Source: Avance Clinical

Sectors: BioTech, Healthcare & Pharm, Clinical Trials

http://www.acnnewswire.com

From the Asia Corporate News Network

Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Source : ACN Newswire

You may also like

12345678............................................................................................................................................+